This success has culminated in the FDA’s approval of four CAR-T-cell therapies directed against the CD19 protein: axicabtagene ciloleucel and lisocabtagene maraleucel for diffuse large B-cell lymphoma (DLBCL), brexucabtagene autoleucel for mantle cell lymphoma, and tisagenlecleucel for acute lymphoblastic leukemia (ALL) [6,7,8]. Here, CD19 is linked to diffuse large B-cell lymphoma.